100 related articles for article (PubMed ID: 16314657)
1. Can the reliance of hormone receptor assays of surgical specimens be explained by the fluctuation of estrogen receptor, progesterone receptor, and HER-2 protein expression in tumor samples of premenopausal breast cancer patients?
Alimonti A; Ferretti G; Cognetti F
J Clin Oncol; 2005 Dec; 23(34):8918; author reply 8918-9. PubMed ID: 16314657
[No Abstract] [Full Text] [Related]
2. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
3. Expression analyses of epidermal growth factor receptor and HER-2/neu: no advantage of prediction of recurrence or survival in breast cancer patients.
Beckmann MW; Niederacher D; Massenkeil G; Tutschek B; Beckmann A; Schenko G; Schnürch HG; Bender HG
Oncology; 1996; 53(6):441-7. PubMed ID: 8960138
[TBL] [Abstract][Full Text] [Related]
4. Conversion of hormone and HER-2 receptor in metachronous neck metastases from breast carcinoma.
Nauroth A; Kalder M; Rössler M; Wichmann G; Dietz A; Wiegand S
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1811-1814. PubMed ID: 28429100
[TBL] [Abstract][Full Text] [Related]
5. Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study.
Tangjitgamol S; Ramirez PT; Sun CC; See HT; Jhingran A; Kavanagh JJ; Deavers MT
Int J Gynecol Cancer; 2005; 15(4):646-56. PubMed ID: 16014119
[TBL] [Abstract][Full Text] [Related]
6. [Expressions of Her-2, EGFR, PS-2 and ER in breast cancer and their clinical implications].
Xu L; Bai ZH; Xu RC; Yan H; Wang FJ; Luo RC
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Feb; 26(2):231-3. PubMed ID: 16503540
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas).
Rakha EA; Ellis IO; Reis-Filho JS
Mod Pathol; 2008 Aug; 21(8):1060-1; author reply 1061-2. PubMed ID: 18654595
[No Abstract] [Full Text] [Related]
8. Overexpression of c-erbB-2 oncoprotein and associated pathobiological factors in invasive primary breast cancer.
Ray A; Sharma BK; Kaur S; Sharma S; Sharma JK
Indian J Exp Biol; 2004 Mar; 42(3):253-8. PubMed ID: 15233293
[TBL] [Abstract][Full Text] [Related]
9. Correlation of hormone receptors with Her-2 Neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia.
Arafah M
Turk Patoloji Derg; 2012; 28(1):38-43. PubMed ID: 22207430
[TBL] [Abstract][Full Text] [Related]
10. [Expression of estrogen and progesterone receptors and HER-2 by breast cancer cells].
Zaĭrat'iants OV; Kolobov SV; Akopian IG; Opalenov KV; Barsanova TG
Arkh Patol; 2004; 66(5):9-12. PubMed ID: 15575377
[TBL] [Abstract][Full Text] [Related]
11. [Correlation of Her-2 overexpression with endocrine status and response to tamoxifen treatment in patients with breast cancer].
Zhang J; Zhang JH; Liu Y; Hao XM; Fang ZX; Li SL
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(46):3268-71. PubMed ID: 18396622
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
[TBL] [Abstract][Full Text] [Related]
13. Changes of expression of estrogen and progestrone receptors, human epithelial growth factor receptor 2 and Ki-67 after neoadjuvant chemotherapy in the treatment of breast cancer.
Li ML; Dong Y; Luan SL; Zhao ZH; Ning FL
J Biol Regul Homeost Agents; 2016; 30(4):1059-1065. PubMed ID: 28078854
[TBL] [Abstract][Full Text] [Related]
14. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
15. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer.
Mann GB; Fahey VD; Feleppa F; Buchanan MR
J Clin Oncol; 2005 Aug; 23(22):5148-54. PubMed ID: 16051956
[TBL] [Abstract][Full Text] [Related]
16. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
[TBL] [Abstract][Full Text] [Related]
17. The immunohistochemically "ER-negative, PR-negative, HER2-negative, CK5/6-negative, and HER1-negative" subgroup is not a surrogate for the normal-like subtype in breast cancer.
Yu KD; Shen ZZ; Shao ZM
Breast Cancer Res Treat; 2009 Dec; 118(3):661-3. PubMed ID: 19714461
[No Abstract] [Full Text] [Related]
18. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
[TBL] [Abstract][Full Text] [Related]
19. [Effect of neoadjuvant chemotherapy on estrogen and progesterone receptors and P53 and CerbB-2 in breast cancer].
Bao G; Yang DQ; Zhou B; Liu P; Wang S; Cheng L
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(40):2843-5. PubMed ID: 18167290
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
Rydén L; Jirström K; Haglund M; Stål O; Fernö M
Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
